Overview

A class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve” or the “Company”) (NASDAQ: VERV) and certain of the Company’s former and current senior executive officers alleging violations of the federal securities laws.  The Verve class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired publicly traded Verve securities between August 9, 2022, and April 1, 2024, both dates inclusive (the “Class Period”).  Investors have until October 28, 2024, to seek appointment as lead plaintiff of the Verve class action lawsuit.

Verve describes itself as a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines.  Pertinent to this class action lawsuit is the Heart-1 Phase 1b clinical trial (the “Heart-1 Trial”) of VERVE-101.

The Company describes VERVE-101 as follows: VERVE-101 is a novel, investigational gene editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (“LDL-C”).  VERVE-101 is being developed initially as a treatment for patients with heterozygous familial hypercholesterolemia (“HeFH”), a prevalent and potentially life-threatening subtype of atherosclerotic cardiovascular disease (“ASCVD”).

VERVE-101 consists of messenger RNA expressing an adenine base editor and an optimized guide RNA targeting the PCSK9 gene packaged in an engineered lipid nanoparticle (“LNP”).  The Company described the Heart 1 Trial as follows: the Heart-1 Trial is an open-label Phase 1b clinical trial designed to enroll adult patients with HeFH, established ASCVD, and uncontrolled hypercholesterolemia to evaluate the safety and tolerability of VERVE-101 administration, with additional analyses for pharmacokinetics and changes in blood PCSK9 protein and LDL-C levels.  The single ascending dose portion of the trial has consisted of four dose levels: 0.1 mg/kg [n=3], 0.3 mg/kg [n=3], 0.45 mg/kg [n=6], and 0.6 mg/kg [n=1].

The Verve class action lawsuit alleges that Defendants, throughout the Class Period, provided statements that were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 Trial would be halted; (2) Defendants overstated the potential benefits of its proprietary LNP delivery system (3) as a result, Defendants’ statements about their business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

*          *          *

If you purchased or otherwise acquired publicly traded Verve securities between August 9, 2022, and April 1, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Verve class action lawsuit is October 28, 2024.